- NITROGENOUS CYCLIC COMPOUND AND COLOR CHANGING FILM COMPRISING SAME
-
The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
- -
-
Paragraph 0140-0141
(2020/04/10)
-
- NOVEL BICYCLIC HETEROCYCLIC COMPOUND
-
Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
- -
-
Paragraph 0743; 0744
(2018/09/27)
-
- HETEROCYCLIC COMPOUND
-
The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
- -
-
Paragraph 0783; 0784
(2015/10/28)
-
- Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part i
-
We report analogue-based rational design and synthesis of two novel series of polycyclic heteroarenes, pyrrolo[3,2-b]quinolines and pyrido[2,3-b]indoles, tethered to a biaryl system by a methyl-, ethyl- or propyl ether as PDE10A inhibitors. A number of analogues were prepared with variable chain length and evaluated for their ability to block PDE10A enzyme using a radiometric assay. Detailed SAR analyses revealed that compounds with an ethyl ether linker are superior in potency compared to compounds with methyl or propyl ether linkers. These compounds, in general, showed poor metabolic stability in rat and human liver microsomes. The metabolic profile of one of the potent compounds was studied in detail to identify metabolic liabilities of these compounds. Structural modifications were carried out that resulted in improved metabolic stability without significant loss of potency.
- Das, Sanjib,Harde, Rajendra L.,Shelke, Dnyaneshwar E.,Khairatkar-Joshi, Neelima,Bajpai, Malini,Sapalya, Ratika S.,Surve, Harshada V.,Gudi, Girish S.,Pattem, Rambabu,Behera, Dayanidhi B.,Jadhav, Satyawan B.,Thomas, Abraham
-
supporting information
p. 2073 - 2078
(2014/05/06)
-
- NOVEL KINASE INHIBITORS
-
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them usefu
- -
-
Page/Page column 38
(2008/12/05)
-
- BETA-AMYLOID PET IMAGING AGENTS
-
Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure.
- -
-
Page/Page column 7; 24
(2008/06/13)
-
- OPIOID RECEPTOR ANTAGONISTS
-
A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3', E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for
- -
-
Page/Page column 42-43
(2008/06/13)
-
